Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
COVID-19
212 Articles Available
0
9
Can't find what you're looking for? Try our
advanced search
.
COVID-19 Vaccine
HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine
PR-M11-20-031
Cover Story
Facing the Challenges of the COVID-19 Pandemic: Rentschler Biopharma
PAP-Q4-20-CL-028
Nice Insight Overview
Delivering Vaccines During a Pandemic
PAP-Q4-20-NI-001
COVID-19 vaccine
How COVID-19 Is Reshaping Vaccine Development: Innovations in Vaccine Technology and Partnerships
PAP-Q4-20-CL-007
Virtual Trade Shows
Meeting the Challenges of the Pandemic through Virtual Trade Shows
PAP-Q4-20-CL-011
Small Molecule
The Importance of a Global Leader in Small Molecule Manufacturing During the COVID-19 Pandemic
PAP-Q4-20-CL-025
Digital Marketing
Creating Quality Content for Effective Digital Marketing
PAP-Q4-20-CL-024
COVID-19 Vaccine Distribution
Preparing for COVID-19 Vaccine Distribution Despite Tight Shipping Capacity
PAP-Q4-20-CL-006
Mobile Research Nursing
Mobile Research Nursing: Evolving to Meet Pandemic Challenges
PAP-Q4-20-CL-013
COVID-19 Therapeutics
How an Agile Company Addressed the Pandemic: Moving from Psychiatric Medicines to a COVID-19 Therapeutic
PAP-Q4-20-CL-017
Supply Chain
Nationalism and the Pharmaceutical Supply Chain
PAP-Q4-20-CL-012
There Were No Passengers On This Journey
The Future of Healthcare
How Does Inceptor Bio Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-002
The Future of Healthcare
How Does Pii Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-012
The Future of Healthcare
How Does Avara Pharmaceutical Services Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-011
The Future of Healthcare
How Does Dynamk Capital Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-013
The Future of Healthcare
How Does Evolve Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-005
The Future of Healthcare
How Does ECRI Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-001
COVID-19 Impacts
Q: What do you think is the greatest lesson learned from the COVID-19 pandemic, and what lasting impacts do you foresee over the next 5–10 years?
PAP-Q4-20-NI-006
Roundtable
Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?
PAP-Q4-20-NI-007
Vaccine
Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate
PR-M11-20-026
FDA Authorization
Babson Diagnostics Receives FDA Emergency Use Authorization for its SARS-CoV-2 IgG Antibody Test
PR-M11-20-025
Antibodies
Lilly's Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19
PR-M11-20-023
FDA Authorization
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
PR-M11-20-022
«
0
9
»
